"Anyone have any comments or insights on DAPA HF and or tbe Paragon trial, which seem to have been stars of Escardio?"

Folks can Google and find summaries of these findings. But in general, great news for treating heart failure patients. Apabetalone has not been tested previously in heart failure patients, and from my understanding BETonMACE excluded heart failure patients. But it will be interesting when the full BETonMACE data is analyzed to see if the apabetalone group had a decreased incidence of newly diagnosed heart failure or decreased hospitalization for heart failure. Heart failure, CKD, diabetes and other cardiovascular diseases often co-exist and share similar risk factors (good review here). Could be an additional heart failure benefit of apabetalone hidden in the BETonMACE data. And then another trial for another time. First things first, nail BETonMACE!

BearDownAZ